These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 28004598)

  • 1. Natalizumab treatment of multiple sclerosis: new insights.
    Delbue S; Comar M; Ferrante P
    Immunotherapy; 2017 Jan; 9(2):157-171. PubMed ID: 28004598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Asymptomatic reactivation of JC virus in patients treated with natalizumab.
    Warnke C; Adams O; Kieseier BC
    N Engl J Med; 2009 Dec; 361(25):2489; author reply 2489-90. PubMed ID: 20050216
    [No Abstract]   [Full Text] [Related]  

  • 3. Asymptomatic reactivation of JC virus in patients treated with natalizumab.
    Chen Y; Bord E; Tompkins T; Miller J; Tan CS; Kinkel RP; Stein MC; Viscidi RP; Ngo LH; Koralnik IJ
    N Engl J Med; 2009 Sep; 361(11):1067-74. PubMed ID: 19741227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progressive multifocal leukoencephalopathy and multiple sclerosis: lessons from natalizumab.
    Langer-Gould A; Steinman L
    Curr Neurol Neurosci Rep; 2006 May; 6(3):253-8. PubMed ID: 16635435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fatal natalizumab-associated progressive multifocal leukoencephalopathy with initial low JCV antibody index in a multiple sclerosis patient.
    Hay M; Leguy S; Cahagne V; Lassalle N; Le Page E; Michel L
    Rev Neurol (Paris); 2024 Jun; 180(6):565-567. PubMed ID: 38429158
    [No Abstract]   [Full Text] [Related]  

  • 6. Influenza vaccination increases anti-JC virus antibody levels during treatment with Natalizumab: Case report.
    Miranda Acuña JA; Weinstock-Guttman B
    Mult Scler Relat Disord; 2016 Sep; 9():54-5. PubMed ID: 27645344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natalizumab for Multiple Sclerosis: A Case in Point for the Impact of Translational Neuroimmunology.
    Shirani A; Stüve O
    J Immunol; 2017 Feb; 198(4):1381-1386. PubMed ID: 28167648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natalizumab-treated patients at high risk for PML persistently excrete JC polyomavirus.
    Werner MH; Huang D
    J Neurovirol; 2016 Dec; 22(6):871-875. PubMed ID: 27198748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natalizumab in relapsing-remitting multiple sclerosis.
    Outteryck O
    Expert Rev Neurother; 2016 May; 16(5):471-81. PubMed ID: 27008031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fingolimod treatment after natalizumab-related progressive multifocal leukoencephalopathy: three new cases.
    Peaureaux D; Pignolet B; Biotti D; Bucciarelli F; Gaina J; Bucur C; Clanet M; Martin-Blondel G; Brassat D
    Mult Scler; 2015 Apr; 21(5):671-2. PubMed ID: 25305251
    [No Abstract]   [Full Text] [Related]  

  • 11. Biomarkers identification for PML monitoring, during Natalizumab (Tysabri®) treatment in Relapsing-Remitting Multiple Sclerosis.
    Lanza Cariccio V; Bramanti P; Mazzon E
    Mult Scler Relat Disord; 2018 Feb; 20():93-99. PubMed ID: 29353737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JC polyomavirus expression and bell-shaped regulation of its SF2/ASF suppressor during the follow-up of multiple sclerosis patients treated with natalizumab.
    Uleri E; Ibba G; Piu C; Caocci M; Leoni S; Arru G; Serra C; Sechi G; Dolei A
    J Neurovirol; 2017 Apr; 23(2):226-238. PubMed ID: 27812788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab.
    Ziemssen T; Gass A; Wuerfel J; Bayas A; Tackenberg B; Limmroth V; Linker R; Mäurer M; Haas J; Stangel M; Meergans M; Harlin O; Hartung HP
    BMC Neurol; 2016 Jul; 16():98. PubMed ID: 27405225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis.
    McCormack PL
    Drugs; 2013 Sep; 73(13):1463-81. PubMed ID: 23912625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis.
    Schröder A; Lee DH; Hellwig K; Lukas C; Linker RA; Gold R
    Arch Neurol; 2010 Nov; 67(11):1391-4. PubMed ID: 20625069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early reduction of the splicing factor2/alternative splicing factor: a cellular inhibitor of the JC polyomavirus in natalizumab-treated MS patients long before developing progressive multifocal leukoencephalopathy.
    Piu C; Ibba G; Bertoli D; Capra R; Uleri E; Serra C; Imberti L; Dolei A
    J Neurovirol; 2020 Feb; 26(1):133-137. PubMed ID: 31468472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High cumulative JC virus seroconversion rate during long-term use of natalizumab.
    Vennegoor A; van Rossum JA; Leurs C; Wattjes MP; Rispens T; Murk JL; Uitdehaag BM; Killestein J
    Eur J Neurol; 2016 Jun; 23(6):1079-85. PubMed ID: 27018481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natalizumab: Perspectives from the Bench to Bedside.
    Shirani A; Stüve O
    Cold Spring Harb Perspect Med; 2018 Dec; 8(12):. PubMed ID: 29500304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natalizumab Affects T-Cell Phenotype in Multiple Sclerosis: Implications for JCV Reactivation.
    Iannetta M; Zingaropoli MA; Bellizzi A; Morreale M; Pontecorvo S; D'Abramo A; Oliva A; Anzivino E; Lo Menzo S; D'Agostino C; Mastroianni CM; Millefiorini E; Pietropaolo V; Francia A; Vullo V; Ciardi MR
    PLoS One; 2016; 11(8):e0160277. PubMed ID: 27486658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natalizumab-associated progressive multifocal leukoencephalopathy: successful treatment without plasma exchange and its associated risks.
    Maloney E; Molloy A; Al Hussona M; O'Donnell L; Killeen R; McGuigan C
    J Neurol; 2017 Feb; 264(2):401-403. PubMed ID: 28039520
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.